Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Absci Raises Oversubscribed $12m Series C To Fuel Commercialization Of Its Groundbreaking Protein Expression Platform
Venture Capital

Absci Raises Oversubscribed $12m Series C To Fuel Commercialization Of Its Groundbreaking Protein Expression Platform

by vcaonline.com posted 9months ago 233 views
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression PlatformThe Series C Round led by Asahi Glass Co., Ltd. "AGC" includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge. VANCOUVER, Wash., May 30, 2018-- AbSci, a global leader in biomanufacturing technologies, today announced the completion of an over-subscribed $12 million Series C financing. As a part of the financing, AGC Biologics' President and CEO, Dr. Gustavo Mahler will join AbSci's Board of Directors.

In this article